TGAT
4XT
Market cap24mUSD
, Last price
EUR
Name
BioNxt Solutions Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
15.60%
Rev. gr., 5y
-33.54%
Revenues
0k
-100.00%
Net income
-7m
L+32.27%
CFO
-5m
L+71.25%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
BioNxt Solutions Inc., a bioscience firm established in 2017 and headquartered in Vancouver, Canada, conducts operations across Germany, Switzerland, Austria, Israel, and Canada. The company is actively involved in developing advanced drug delivery methods, such as transdermal patches and oral dissolvable films, designed for the administration of neurological medications. Additionally, BioNxt focuses on psychedelic medicine, creating treatments for various mental health conditions including depression, anxiety, addiction, and trauma-related stress disorder. The company also pioneers point-of-care diagnostic solutions, which include rapid diagnostics and biosensor screening tests aimed at facilitating early disease detection, enhancing treatment efficacy, and improving overall disease management. Specific examples of these diagnostics are a COVID-19 PCR kit, an oral biosensor for peri-implantitis, and oral biosensors for H1N1 (swine flu) and H5N1 (avian flu). Beyond product development, BioNxt provides analytical testing and consulting services. Its business scope further encompasses pathogen and oral health diagnostic and screening tests, thin film drug formulation, and the production and formulation of psychedelic pharmaceuticals. The company rebranded from its former name, XPhyto Therapeutics Corp., to BioNxt Solutions Inc. in November 2022.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||